Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab-based neoadjuvant/adjuvant combination therapy for resectable locally advanced NSCLC
ChiCTR2200062465Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in non-small cell lung cancer (NSCLC) and bronchial carcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2200062465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062465.